olivLaw · US equity research
AstraZeneca PLC AZN
Pharmaceutical Preparations · SIC 2834 · Vertical: Pharmaceutical Preparations (SIC 2834)
AstraZeneca PLC is a British pharmaceutical company that develops and sells medicines in oncology, cardiovascular, renal and metabolism, respiratory and immunology, and rare diseases. The company moved its ordinary shares to a direct listing on the New York Stock Exchange in February 2026, which makes its exposure to the US market relevant.
The AI analysis may be outdated: new filings came after its sources (see the «AI analysis» section).
At the close of 04 Nov 2026, AstraZeneca PLC (AZN) stock was 189.01 USD (+2.79% on the day), with P/E 28.9 on diluted EPS of 6.54 USD over the last 12 months, dividend yield 1.66%, beta 0.33, 52-week range 155.62–209.48 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 73.5
- overbought (≥ 70)
- Bollinger (20, 2)
- 150.93 – 189.44
- in the upper half of the band · %B 0.99 · band width 22.6%
- SMA 50 / 200
- 165.62 / 180.17
- mixed trend
- MACD (12, 26, 9)
- 5.92 / 3.68
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +20.8% | −1.1% | +21.8 pp | — |
| 3 months | +17.0% | −0.5% | +17.5 pp | — |
| 6 months | +2.2% | +4.4% | −2.2 pp | — |
| Year to date | +2.8% | +12.3% | −9.5 pp | — |
| 1 year | +15.2% | +13.5% | +1.7 pp | −9.2% |
| 3 years | +47.8% | +76.4% | −28.7 pp | +50.7% |
| 5 years | +49.8% | +63.7% | −13.9 pp | — |
Price returns, dividends excluded.
Quarterly results
ESEF annual reports carry no quarters: the results are annual (below).
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Today's P/E sits at the 20 percentile of its own 10-quarter history (min 19.8, median 38.2, max 1,456.3; quarters with earnings only).
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 22.1 bn | 24.4 bn | 26.6 bn | 37.4 bn | 44.4 bn | 45.8 bn | 54.1 bn | 58.7 bn |
| Revenue YoY | −1.7% | +10.4% | +9.2% | +40.6% | +18.5% | +3.3% | +18.0% | +8.6% |
| Net income | 2.2 bn | 1.3 bn | 3.2 bn | 112.0 m | 3.3 bn | 6.0 bn | 7.0 bn | 10.2 bn |
| Net income YoY | −28.2% | −38.1% | +139.4% | −96.5% | +2,835.7% | +81.1% | +18.1% | +45.3% |
| Diluted EPS | 1.70 | 1.03 | 2.44 | 0.08 | 2.11 | 3.81 | 4.50 | 6.54 |
| Diluted EPS YoY | −28.3% | −39.4% | +136.9% | −96.7% | +2,537.5% | +80.6% | +18.1% | +45.3% |
| net % | 9.8% | 5.5% | 12.0% | 0.3% | 7.4% | 13.0% | 13.0% | 17.4% |
| Free cash flow | 1.6 bn | 2.0 bn | 3.8 bn | 4.9 bn | 8.7 bn | 9.0 bn | 9.9 bn | 11.8 bn |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 5.7 bn USD
- Financial debt
- 24.7 bn USD
- Net debt
- 19.0 bn USD
- Equity
- 48.7 bn USD
- Total assets
- 114.1 bn USD
- Debt / equity
- 0.51x
- Current ratio
- 0.94x
- ROE
- 22.8%
- ROA
- 9.4%
- FCF margin
- 20.0%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 26.6 bn | 37.4 bn | 44.4 bn | 45.8 bn | 54.1 bn | 58.7 bn | SEC (XBRL)· 24 Feb 2026verified |
| Cost of revenue | 5.3 bn | 12.4 bn | 12.4 bn | 8.3 bn | 10.2 bn | 10.6 bn | SEC (XBRL)· 24 Feb 2026verified |
| Gross profit | 21.3 bn | 25.0 bn | 32.0 bn | 37.5 bn | 43.9 bn | 48.1 bn | SEC (XBRL)· 24 Feb 2026verified |
| Research & development | 6.0 bn | 9.7 bn | 9.8 bn | 10.9 bn | 13.6 bn | 14.2 bn | SEC (XBRL)· 24 Feb 2026verified |
| Operating income | 5.2 bn | 1.1 bn | 3.8 bn | 8.2 bn | 10.0 bn | 13.7 bn | SEC (XBRL)· 24 Feb 2026verified |
| Interest expense | 1.3 bn | 1.3 bn | 1.3 bn | 1.6 bn | 1.7 bn | 1.7 bn | SEC (XBRL)· 24 Feb 2026verified |
| Pre-tax income | 3.9 bn | -265.0 m | 2.5 bn | 6.9 bn | 8.7 bn | 12.4 bn | SEC (XBRL)· 24 Feb 2026verified |
| Income tax | 772.0 m | -380.0 m | -792.0 m | 938.0 m | 1.7 bn | 2.2 bn | SEC (XBRL)· 24 Feb 2026verified |
| Net income | 3.2 bn | 112.0 m | 3.3 bn | 6.0 bn | 7.0 bn | 10.2 bn | SEC (XBRL)· 24 Feb 2026verified |
| Diluted EPS | 2.44 | 0.08 | 2.11 | 3.81 | 4.50 | 6.54 | SEC (XBRL)· 24 Feb 2026verified |
| Weighted average diluted shares | 1.3 bn | 1.4 bn | 1.6 bn | 1.6 bn | 1.6 bn | 1.6 bn | SEC (XBRL)· 24 Feb 2026verified |
| Dividend per share | 2.80 | 2.80 | 2.90 | 2.90 | 2.97 | 3.13 | SEC (XBRL)· 24 Feb 2026verified |
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 7.8 bn | 6.3 bn | 6.2 bn | 5.8 bn | 5.5 bn | 5.7 bn | SEC (XBRL)· 24 Feb 2026verified |
| Receivables | 7.0 bn | 9.6 bn | 10.5 bn | 12.1 bn | 13.0 bn | 15.2 bn | SEC (XBRL)· 24 Feb 2026verified |
| Inventories | 4.0 bn | 9.0 bn | 4.7 bn | 5.4 bn | 5.3 bn | 6.6 bn | SEC (XBRL)· 24 Feb 2026verified |
| Current assets | 19.5 bn | 26.2 bn | 22.6 bn | 25.1 bn | 25.8 bn | 28.7 bn | SEC (XBRL)· 24 Feb 2026verified |
| Property, plant & equipment, net | 8.3 bn | 9.2 bn | 8.5 bn | 9.4 bn | 10.3 bn | 13.0 bn | SEC (XBRL)· 24 Feb 2026verified |
| Goodwill | 11.8 bn | 20.0 bn | 19.8 bn | 20.0 bn | 21.0 bn | 21.2 bn | SEC (XBRL)· 24 Feb 2026verified |
| Intangibles (excl. goodwill) | 20.9 bn | 42.5 bn | 39.3 bn | 38.1 bn | 37.2 bn | 37.8 bn | SEC (XBRL)· 24 Feb 2026verified |
| Total assets | 66.7 bn | 105.4 bn | 96.5 bn | 101.1 bn | 104.0 bn | 114.1 bn | SEC (XBRL)· 24 Feb 2026verified |
| Accounts payable | 15.8 bn | 18.9 bn | 19.0 bn | 22.4 bn | 22.5 bn | 25.3 bn | SEC (XBRL)· 24 Feb 2026verified |
| Long-term debt | 17.5 bn | 28.1 bn | 23.0 bn | 22.4 bn | 26.5 bn | 24.7 bn | SEC (XBRL)· 24 Feb 2026verified |
| Current liabilities | 20.3 bn | 22.6 bn | 26.3 bn | 30.5 bn | 27.9 bn | 30.6 bn | SEC (XBRL)· 24 Feb 2026verified |
| Total liabilities | 51.1 bn | 66.1 bn | 59.4 bn | 62.0 bn | 63.2 bn | 65.4 bn | SEC (XBRL)· 24 Feb 2026verified |
| Equity | 15.6 bn | 39.3 bn | 37.1 bn | 39.2 bn | 40.9 bn | 48.7 bn | SEC (XBRL)· 24 Feb 2026verified |
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | 4.8 bn | 6.0 bn | 9.8 bn | 10.3 bn | 11.9 bn | 14.6 bn | SEC (XBRL)· 24 Feb 2026verified |
| Capex | 961.0 m | 1.1 bn | 1.1 bn | 1.4 bn | 1.9 bn | 2.8 bn | SEC (XBRL)· 24 Feb 2026verified |
| Free cash flow | 3.8 bn ≈ | 4.9 bn ≈ | 8.7 bn ≈ | 9.0 bn ≈ | 9.9 bn ≈ | 11.8 bn ≈ | SEC (XBRL)· 24 Feb 2026derived |
| Investing cash flow | -285.0 m | -11.1 bn | -3.0 bn | -4.1 bn | -8.0 bn | -6.8 bn | SEC (XBRL)· 24 Feb 2026verified |
| Financing cash flow | -2.2 bn | 3.6 bn | -6.8 bn | -6.6 bn | -4.0 bn | -7.5 bn | SEC (XBRL)· 24 Feb 2026verified |
| Dividends paid | 3.6 bn | 3.9 bn | 4.4 bn | 4.5 bn | 4.6 bn | 5.0 bn | SEC (XBRL)· 24 Feb 2026verified |
| Share repurchases | — | 149.0 m | — | — | 81.0 m | 521.0 m | SEC (XBRL)· 24 Feb 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
Score: 77 / 100
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: unavailable
Key indicators
Coverage and freshness
Score by group
- Valuation59
- Balance sheet65
- Quality78
- Growth91
- Returns100
Estimated value range
The combined range = the median of the valid methods' low, central and high values; it is not a probability interval and does not cover every result. Envelope of all methods: 41.13 – 285.40 USD.
Valuation assumptions are editorial choices, not measured; beta is not measured.
Method ranges (USD per share)
— — Mid · ▏ Price
Valuation methods
- DCF (discounted cash flow)unavailable · input data missing
- Peers: EV/EBITDAunavailable · input data missing
- Peers: P/E97.76 – 285.40 (Mid 190.62)14 companies used · median multiple 29.1x · quartiles 14.9x – 43.6xABBV, ABT, ALNY, AUPH, BMY, JNJ, LLY, NATR, PFE, REGN, RPRX, UTHR, VRTX, ZTS
- Dividend discount (DDM)41.13 – 55.31 (Mid 47.18)
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Neutral profile · Score 77/100
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | 17.5% | 67 (vs peers) | 16% |
| Net margin · Quality | 17.4% | 74 (vs peers) | 10% |
| FCF conversion · Quality | 115.1% | 100 (on a fixed band) | 10% |
| Revenue CAGR 3Y · Growth | 9.8% | 82 (on a fixed band) | 13% |
| EPS CAGR 3Y · Growth | 45.8% | 100 (on a fixed band) | 13% |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | 8.1x | 100 (on a fixed band) | 10% |
| Current ratio · Balance sheet | 0.9x | 12 (on a fixed band) | 6% |
| P/E (TTM) · Valuation | 28.9x | 59 (vs peers) | 16% |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | unavailable | unavailable | — |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | 42.3% | 100 (on a fixed band) | 6% |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet65/100 · 2/3 factors with a value
- Growth91/100 · 2/2 factors with a value
- Quality78/100 · 3/3 factors with a value
- Returns· partial100/100 · 1/2 factors with a value
- Valuation· partial59/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
ASTRAZENECA PLC (AZN). Latest full fiscal year: 2025; data up to 2025-12-31.
Figures computed from the financial statements: revenue 58.7 bn USD in 2025; YoY growth 8.6%; net margin 17.4%; ROE 22.9%.
The estimated value range is 69.44–170.36 USD per share (median of 2 methods, agreement: low); assumptions are illustrative. Against the central value of 118.90 USD, the price of 189.01 USD leaves a potential of -37.1% (value / price − 1) and a margin of safety of -59.0% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
olivLaw score 77/100, methodological classification: neutral profile (score, margin of safety and method agreement together; not a judgement of the right price). Groups assessed only in part: returns, valuation. Not investment advice.
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Net margin: 17.4%
- FCF conversion: 115.1%
- Revenue CAGR 3Y: 9.8%
- EPS CAGR 3Y: 45.8%
- Interest coverage: 8.1x
- Payout ratio (FCF): 42.3%
What contradicts it
- Current ratio: 0.9x
- The price is above the estimated value range
- The valuation methods diverge
Not assessed (insufficient data or a ratio without meaning): Net debt / EBITDA, EV/EBITDA, FCF yield, Shareholder yield (distributions).
Versus the vertical median
Pharmaceutical Preparations (SIC 2834) · same industry (4-digit SIC) · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| LLYEli Lilly And Company | 1,334.0 bn | 46.0 | 86.1% | 31.9% | +44.7% | +32% / +140% |
| JNJJohnson & Johnson | 665.2 bn | 41.9 | 20.0% | 16.2% | +6.0% | +34% / +79% |
| ONCBeone Medicines Ltd. | 558.4 bn | 869.9 | 14.7% | 10.7% | +40.2% | +11% / +102% |
| ABBVAbbVie Inc. | 521.1 bn | 50.7 | — | 15.7% | +8.6% | +29% / +107% |
| MRKMerck & Co., Inc. | 370.7 bn | 154.7 | 5.1% | 3.6% | +1.3% | +43% / +47% |
| ABTAbbott Laboratories | 200.1 bn | 43.0 | 9.2% | 9.7% | +5.7% | −10% / +11% |
| PFEPfizer Inc | 175.5 bn | 43.9 | 4.4% | 6.3% | −1.6% | +20% / +1% |
| VRTXVertex Pharmaceuticals Inc | 139.2 bn | 35.3 | 20.8% | 30.7% | +8.9% | +27% / +55% |
| BMYBristol-Myers Squibb Company | 131.2 bn | 14.2 | 44.1% | 18.5% | −0.2% | +30% / +30% |
| TEVATeva Pharmaceutical Industries Limited | 48.8 bn | 97.4 | 6.6% | 3.6% | +4.3% | +56% / +326% |
| ZTSZoetis Inc. | 36.9 bn | 14.7 | 64.4% | 27.5% | +2.3% | −30% / −50% |
| ROIVRoivant Sciences Ltd. | 27.6 bn | — | -6.2% | -3,535.0% | −71.6% | +84% / +300% |
| RPRXRoyalty Pharma plc | 26.2 bn | 47.7 | 6.9% | 25.7% | +5.1% | +69% / +150% |
| UTHRUnited Therapeutics Corporation | 25.9 bn | 23.0 | 19.1% | 38.6% | +10.6% | +25% / +154% |
| INSMInsmed Inc | 24.1 bn | — | -72.5% | -39.9% | +66.7% | −47% / +340% |
| VTRSViatris Inc. | 22.1 bn | — | -23.6% | -23.9% | −3.0% | +80% / +109% |
| ALNYAlnylam Pharmaceuticals, Inc. | 21.6 bn | 8.1 | 126.6% | 52.8% | +65.2% | −64% / −4% |
| ORKAOruka Therapeutics, Inc. | 6.7 bn | — | -18.2% | — | unavailable | +237% / +364% |
| IONSIonis Pharmaceuticals, Inc. | 6.7 bn | — | -105.5% | -64.7% | +33.8% | −51% / −19% |
| IDYAIDEAYA Biosciences, Inc. | 3.1 bn | — | -38.5% | -1,149.6% | +3,024.4% | −9% / +3% |
| RADXRadiopharm Theranostics Limited | 3.1 bn | — | -109.2% | -1,055.3% | +1,114.3% | −81% / unavailable |
| AUPHAurinia Pharmaceuticals Inc. | 2.3 bn | 7.5 | 61.4% | 97.7% | +20.4% | +6% / +98% |
| QUREuniQure N.V. | 1.6 bn | — | -89.0% | -1,154.8% | −40.6% | −16% / +240% |
| URGNUroGen Pharma Ltd. | 1.4 bn | — | — | -26.3% | +21.4% | −0% / +118% |
| ASMBAssembly Biosciences, Inc. | 404.6 m | — | -0.0% | -0.1% | +153.5% | −47% / +137% |
1- and 3-year price returns: for AZN from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Scenarios are not available. input data missing
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 24 Feb 2026; since then the company filed 6-K (02 Nov 2026), 6-K (30 Oct 2026), 6-K (27 Oct 2026), 6-K (22 Oct 2026), 6-K (05 Oct 2026).
In brief
AstraZeneca PLC is a British pharmaceutical company that develops and sells medicines in oncology, cardiovascular, renal and metabolism, respiratory and immunology, and rare diseases. The company moved its ordinary shares to a direct listing on the New York Stock Exchange in February 2026, which makes its exposure to the US market relevant.
SWOT
Strengths
Weaknesses
- Medicine development is slow and costly, and many projects fail at various stages 1.
- Reliance on third parties for active ingredients and packaging components may create vulnerabilities in the supply chain 1.
- Emerging markets bring difficulties linked to economic and political instability and to protection against fraud 1.
Opportunities
- Development in oncology and rare diseases could create new revenue sources if phase III studies succeed 1.
- The use of artificial intelligence could accelerate drug discovery and optimise manufacturing processes 1.
- Collaboration and licensing agreements can extend the portfolio without developing every product in-house 1.
Risks
- Pipeline failure or delayhigh
Medicine development can fail at any stage because of unfavourable clinical data or refusal of approval, which would affect future revenue 1.
- Pricing pressurehigh
Cost-control measures and joint procurement initiatives could reduce prices and volumes sold in several countries 1.
- Supply chain disruptionmedium
Dependence on external suppliers and manufacturing compliance risks could lead to product shortages or recalls 1.
- IT and cyber risksmedium
Disruptions to IT systems or breaches of data security could damage reputation and lead to regulatory sanctions 1.
- Data and artificial intelligence managementlow
Changing legal requirements on personal data and on the use of artificial intelligence could raise costs or limit certain operations 1.
Investment thesis
What would need to be true (bull case)
- If several phase III molecules in oncology and cardiovascular areas meet their objectives, the portfolio could generate sustained revenue growth 1.
- The direct listing on the New York Stock Exchange could bring a wider investor base and greater visibility in the US market 1.
- Experience in acquisitions and collaborations could allow the company to fill its pipeline with new assets in areas of interest 1.
What would break the thesis
- If price pressure spreads, revenue from existing products could decline faster than expected 1.
- Failure of important molecules in clinical studies could reduce the value of the pipeline and affect investor confidence 1.
- Patent expiry and the entry of competitors with cheaper versions could erode revenue from established products 1.
What to watch
- Results of phase III studies in oncology and cardiovascular areas2026
- Development of the direct listing on the New York Stock Exchange and trading volume2026
- Regulatory decisions on approval of new molecules2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 24 Feb 2026; since then the company filed 6-K (02 Nov 2026), 6-K (30 Oct 2026), 6-K (27 Oct 2026), 6-K (22 Oct 2026), 6-K (05 Oct 2026).
The business
The company's strategy rests on a portfolio of innovative products developed in-house and through licensing and collaboration agreements, and it acknowledges that developing a medicine is a complex, risky and lengthy process 1. Revenue depends on the successful launch of new products and on keeping patients' access to treatments, under pressure on prices and reimbursement 1.
The company describes its pricing approach through four principles: access, value, sustainability and equity, applied differently in each country 1. Its pipeline includes products in early, phase II and phase III stages, with a focus on oncology, and a large number of clinical trials are under way 1.
Segments
Oncology
Oncology is the broadest area of the company's pipeline, with several molecules in phase III, including PD-L1 inhibitors, antibody-drug conjugates and PARP inhibitors, according to the development list in the annual report 1. Several medicines in this area are reported as launched in major markets 1.
Cardiovascular, renal and metabolism
In cardiovascular, renal and metabolic areas, the pipeline includes molecules such as baxdrostat, balcinrenone and zibotentan, some in phase III and others in phase II studies, with indications for hypertension, heart failure and chronic kidney disease 1. The company also lists a PCSK9 inhibitor in development for dyslipidaemia 1.
Market context
The pharmaceutical market is heavily regulated, and approvals depend on authorities such as the FDA in the United States and the European Medicines Agency, which can require additional studies or refuse approval 1. Cost pressures, demands for price transparency and joint procurement initiatives create a difficult commercial environment, especially in emerging markets 1.
Demand for innovative medicines remains high in oncology and rare diseases, and companies with broad portfolios may benefit from this dynamic, but also from the growing complexity of rules on data and artificial intelligence 1. The company notes that safety and efficacy standards and policy changes can alter launch timing 1.
Trends
- Pressure on pricesheadwind
Rising cost-containment measures and the emergence of joint procurement mechanisms could limit prices and volumes if governments extend these policies 1.
- Oncology pipelinetailwind
The large number of phase III molecules and recent oncology launches could support revenue growth if studies meet their objectives 1.
- Regulation of data and artificial intelligencemixed
Stricter legal requirements on data, including health and genomic data, could raise compliance costs but could also speed drug discovery if managed effectively 1.
- Exposure to the US marketmixed
The direct listing on the New York Stock Exchange in February 2026 could increase the company's visibility in the United States, where it also holds important assets from the MedImmune and Alexion acquisitions 1.
Competitive position
The company faces competition from other pharmaceutical companies pursuing the same indications, and a delayed launch may allow rivals to reach the market first 1. Competition for asset acquisitions and licences can lead to large premiums over book or market value 1.
In oncology, speed to market is critical because competitors run a very large number of clinical trials, and delays can shorten the term of patent exclusivity 1. The company acknowledges that not all partnerships will succeed 1.
- Other pharmaceutical companies
The source does not name competitors, but describes general industry competition, including for asset acquisitions and for shared therapeutic indications 1.
- Companies with oncology studies
Competitors developing similar molecules in oncology could reach the market first, which could reduce the company's advantage if its launch is delayed 1.
- Generic and biosimilar producers
Expiry of patents on existing products may allow entry of competitors with cheaper versions, a threat the report links to erosion of intellectual property rights 1.
- Companies with cell and bispecific therapies
In CAR-T and bispecific therapies, competitors develop molecules in the same haematological and oncology indications, according to the company's pipeline 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- Мэрия Москвы не видит рисков в строительстве в столице фармзавода AstraZenecaInterfax Russia (RU) · 05 Nov 2026 · RU
- Democrats get their health agenda ready ahead of takeoverThe Hill · 04 Nov 2026 · EN
- AI Fighter Pilots Academy, where Saab trains its AI AgentsEuropean Defence Review · 03 Nov 2026 · RO
- STAT+: Pharmalittle: We’re reading about payments to Russian middlemen, a possible Dupixent rival, and moreSTAT News · 02 Nov 2026 · EN
- AstraZeneca to launch new cancer drugs lineTASS (RU, EN) · 02 Nov 2026 · EN
- Рынки акций Европы преимущественно снизились в пятницуInterfax Russia (RU) · 02 Nov 2026 · RU
- Neoadjuvant botensilimab with or without balstilimab in pMMR and dMMR colon cancer: the phase 2 UNICORN trialNature Medicine · 02 Nov 2026 · EN
- Global, regional and national burden of cervical cancer in 1990–2023 with forecasts to 2050: a Global Burden of Disease studyNature Medicine · 02 Nov 2026 · EN
- Novel chemical reaction expands options for building DNA-encoded librariesPhys.org · 30 Oct 2026 · EN
- STAT+: Pharmalittle: We’re reading about AstraZeneca cost-cutting, Sun Pharma facility problems, and moreSTAT News · 30 Oct 2026 · EN
- 5-year outcomes of chemotherapy de-escalation in HER2-positive early breast cancer and exploratory circulating tumor DNA analyses from the randomized phase 2 PHERGain trialNature Medicine · 29 Oct 2026 · EN
- Insights into early-onset colorectal cancer from a single-nucleus RNA-seq atlas of colorectal cancer across the age continuumNature Medicine · 29 Oct 2026 · EN
- VIDEO UPDATE Accident feroviar în Spania: Bilanțul tragediei a urcat la 64 de morți - AgerpresAgerpres · 28 Oct 2026 · RO
- VIDEO UPDATE Spania: Cel puțin 30 de morți în urma ciocnirii a două trenuri - AgerpresAgerpres · 28 Oct 2026 · RO
- VIDEO LIVE UPDATE Accident feroviar în Spania: Bilanțul tragediei a urcat la 64 de morți - AgerpresAgerpres · 28 Oct 2026 · RO
- Două trenuri de mare viteză s-au ciocnit în Spania - AgerpresAgerpres · 28 Oct 2026 · RO
- Birth weight, cognitive reserve and outcomes after first-episode psychosisNature Mental Health · 28 Oct 2026 · EN
- Progres major în tratamentul cancerului gastric: medicamentul experimental AstraZeneca reduce riscul de deces cu 53% față de chimioterapieLibertatea.ro · 26 Oct 2026 · RO
- STUDIU: Două medicamente combinate prelungesc perioada de supravieţuire în cazul pacienților diagnosticați cu cancer pulmonarG4Media · 26 Oct 2026 · RO
- Neoadjuvant durvalumab plus chemotherapy in resectable or borderline resectable non-small-cell lung cancer: the phase 2 MDT-BRIDGE trialNature Medicine · 26 Oct 2026 · EN
SEC filings
- Current report (foreign issuer)02 Nov 2026
- Current report (foreign issuer)02 Nov 2026
- Current report (foreign issuer)30 Oct 2026
- Current report (foreign issuer)27 Oct 2026
- Current report (foreign issuer)22 Oct 2026
- Current report (foreign issuer)05 Oct 2026
- Current report (foreign issuer)02 Oct 2026
- Current report (foreign issuer)01 Oct 2026
- Current report (foreign issuer)01 Oct 2026
- Current report (foreign issuer)29 Sept 2026
Sources
- [1] Form 20-F, fiscal year ended 2025-12-31 · SEC / AstraZeneca PLC · 24 Feb 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.